PHARMeMED - Latest News, Events & Opportunities
Latest News
Novo Nordisk, Lilly see insatiable demand for weight-loss drugs: Novo Nordisk and Eli Lilly (LLY.N) both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their availability. Read
How French pharma giant Sanofi is betting big on AI: The benefits of artificial intelligence (AI) in shaping clinical research and trials have given rise to many new AI-driven biotech startups. Read
Colorectal cancer - Aspirin found to activate protective genes: LMU researchers have identified a signaling pathway by which aspirin can inhibit colorectal cancer. Read
Lilly's blockbuster Mounjaro boosts third quarter results, supply issues persist: Surging demand for Eli Lilly's diabetes drug Mounjaro, which is also being used off-label for weight loss, led to a surprise third-quarter profit, but the drugmaker on Thursday said it expects supply constraints for some time as it adds manufacturing capacity. Read
'Lab on a chip' genetic test device can identify viruses within three minutes with top-level accuracy: A virus diagnosis device that gives lab-quality results within just three minutes has been invented by engineers at the University of Bath, who describe it as the "world's fastest COVID test." Read
Pfizer’s Litfulo approved by MHRA for adults and adolescents with alopecia areata: Pfizer’s Litfulo (ritlecitinib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat severe alopecia areata in patients aged 12 years and older. Read
Researchers develop approach that could help supercharge T-cell therapies against solid tumors: Researchers at the National Institutes of Health have developed a way to potentially increase the effectiveness of T cell–based immunotherapy treatments, such as CAR T-cell therapy, against solid tumors. Read
Could this be the start of a new era for PI3K drugs? There is hope that a rich biotech pipeline will produce a second generation of PI3K drugs after issues with the first generation from the class had brought up concerns. Read
'Injectable tissue prosthesis' offers new approach for regenerating damaged muscle/nerve: In a study published in the journal Nature, researchers from the Institute of Basic Science (IBS) in South Korea have made significant strides in biomaterial technology and rehabilitation medicine. Read
Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say: Moderna should hit the lower end of its sales target for this year as it only needs to tap a small portion of the private market with its COVID vaccine to reach that goal, according to industry analysts. Read
How Novo Nordisk makes its weight-loss drug Wegovy: Novo Nordisk is spending billions of dollars to boost output and ease shortages of its hugely popular, highly effective weight-loss medicine Wegovy. Read
Scientists excited by AI tool that grades severity of rare cancer: Artificial intelligence is nearly twice as good at grading the aggressiveness of a rare form of cancer from scans as the current method, a study suggests. By recognising details invisible to the naked eye, AI was 82% accurate, compared with 44% for lab analysis.
AstraZeneca and Cellectis enter gene therapy partnership worth over $2.2bn: AstraZeneca (AZ) has announced a collaboration and investment agreement with Cellectis aimed at accelerating the development of therapeutics in areas including oncology, immunology and rare diseases, with the deal potentially worth over $2.2bn. Read
Abbott’s Biowearable Performs Well In U.K. Ahead Of U.S. Launch: Abbott's transition from medical grade CGM technology for diabetics to consumer health monitoring and coaching with Lingo will be a fascinating case study on user's appetite for biometric tracking. Read
Gremlin 1 cells discovery offers hope to treat and reverse osteoarthritis: Current osteoarthritis treatment manages symptoms rather than addressing the underlying disease, but a new University of Adelaide study has shown the condition may be treatable and reversible. Read
High-performance computing could improve therapy for hard-to-treat cancer: Researchers at the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust have revealed that high-performance computing can facilitate a new radiotherapy approach for hard-to-treat cancers. Read
Merck KGaA and Hengrui Pharmaceuticals announce oncology partnership worth over €1.4bn: Merck KGaA has signed a licensing agreement worth over €1.4bn with Jiangsu Hengrui Pharmaceuticals for the rights to its next-generation PARP1 inhibitor HRS-1167 outside of China. Read
THE ALGORITHM HELPING FIND AN UNDERDIAGNOSED HEART CONDITION: What the human eye can't see or might miss.......#AI and #machinelearningcan capture using vast datasets to elucidate the subtle #ecg commonalities that predict higher likely outcomes! Read
GSK's cancer drug Jemperli meets overall survival goal in late-stage trial: British drugmaker GSK said on Monday its cancer drug Jemperli when combined with chemotherapy, met the primary goal of overall survival in patients with advanced or recurrent endometrial cancer in a late-stage trial. Read
FDA approves Santhera’s Duchenne muscular dystrophy drug Agamree: The US Food and Drug Administration (FDA) has approved Santhera Pharmaceuticals’ Agamree (vamorolone) to treat Duchenne muscular dystrophy (DMD) in patients aged two years and older. Read
Extreme heat projected to increase cardiovascular deaths: Cardiovascular-related deaths due to extreme heat are expected to increase between 2036 and 2065 in the United States, according to a study supported by the National Institutes of Health. Read
Pfizer RSV vaccine lags GSK’s as head-to-head competition underway: Pfizer, which dominated COVID vaccine sales, now finds itself looking up at GSK (GSK.L), whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer. Read
Pfizer and BioNTech Report Positive Results for Combined Influenza and COVID-19 Vaccine: #Pfizer and #BioNTech have reported encouraging results from a combined #influenza and #COVID19 vaccine trial. Read
UC Davis Scientists Discover 'Death Switch' to Triggering Cancer Cell Self-Destruction: Scientists from the UC Davis Comprehensive Cancer Center have identified a specific section #epitope on the #CD95 receptor, which could potentially instruct #cancer cells to self-destruct (#apoptosis). Read
Eli Lilly’s Omvoh granted FDA approval for ulcerative colitis: Eli Lilly’s IL-23p19 inhibitor Omvoh (mirikizumab-mrkz) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderately to severely active ulcerative colitis (UC). Read
The problem with potential changes to the biosimilar regulatory framework: It’s critical to ensure patients have increased choice for therapeutic treatments, which is why we shouldn’t limit FDA’s authorities and flexibilities to meet regulatory needs of the future. Read
Liquid Biopsy Provides Earlier Detection of an Inherited Cancer: SickKids, OICR, and UHN researchers created a liquid biopsy for early cancer detection in Li-Fraumeni syndrome (LFS) patients, which could benefit other hereditary cancer syndromes. Read
FDA won’t extend LDT rule comment period: The US Food and Drug Administration (FDA) will not extend the comment period deadline for a proposed rule that would start phasing out its regulatory discretion of laboratory-developed tests (LDT). Read
Scientists isolate 'pre-emerging' bat coronavirus but also identify existing medication that potently neutralizes it: Repeated outbreaks of bat-derived coronaviruses among humans and other mammals have heightened the need for a broad range of therapeutics—monoclonal antibodies and antivirals—treatments that can come immediately "off-the-shelf" to address newly-emerging zoonotic threats. Read
Upcoming Events and Webinars
Digital Implementation: Pharma's Launchpad to the Future Webinar [NOV 09]: Join
Mastering the EU MDR & IVDR Hybrid Workshop [NOV 10]: Join
Legal And IP Protection For New Biotechs [NOV 11/13/23]: Join
iPSC Disease Models as a tool in drug discovery[NOV 08]: Join
Recommended by LinkedIn
Is Board Certification in Medical Affairs right for you?[NOV 08] Join
Merck Journeys: Elevating your Career within Clinical Research - Virtual Event [NOV 07]: Join
Hemophilia Changemakers 2023 Series - Free Webinar [NOV 07, 2023]: Join
IVI-MDD (Major Depressive Order) Value Model [OCT 26 - DEC 16, 2023]: Join
Seminar on Bioprocess and Bioreactors - understand scaling up [NOV 22, 2023]: Join
How to Become a Great Mentor [DEC 05, 2023]: Join
3rd Allogenic Cell Therapies Summit - Europe [JAN 29 -31, 2024]: Join
Genotoxic Impurities - Nitrosamines & Beyond: [NOV 30 - DEC 01, 2023]: Join
Navigating Compliance - UK reach and COSHH [NOV 23]: Join
Revolutionise your Regulatory Content Change Process [NOV 29, 2023]: Join
Clinical Data Disclosure Europe NOV 07, 2023]: Join
Microplastics Webinar [NOV 30,2023]: Join
PHARMA GXP COURSES: Join
Pharma Customer Engagement Europe 2023 [NOV 09 -10, 2023]: Join
3rd Investigator - Initiated Trials Summit [NOV 13 - 14, 2023]: Join
Pharma Digital Health Europe 2023 [NOV 09 -10, 2023]: Join
4th Next-Gen MSL Excellence Summit [NOV 13 - 14, 2023]: Join
Pharma & Patient USA 2023 [NOV 17, 2023]: Join
How biotechs can make informed decisions about switching CROs: Join
4th Edition of the Middle East Pharmaceutical Risk & Compliance Conference [MAR 07, 2024]: Join
Vector Design & Delivery [JAN 16 - 19, 2024]: Join
Latest Jobs
Many of these jobs are not advertised on job boards.